To Light a Candle
V-23 is the code given to an experimental serum manufactured by The Chiron Group. Designed to alleviate the physical effects of vitae addiction caused by Kindred, the drug is similar to methadone in that it is a placebo designed to help users fight mental addiction. The serum has not been widely tested or marketed, and Doctor Poole has been assigned to administer an ad-hoc clinical trial of the drug to Agent Maebh. The drug has so far seemed to work as designed, repressing physical addiction and reaction to vitae with minimal side-effects.
The development of V-23 is an unfolding mystery. Antonin Selzanki and Matsumoto-Sensei are both known contributors to the project, and Matsumoto intimated that there were many other people involved in the development process. The fact that Maebh was specifically selected for a clinical trial indicates that Task Force Valkyrie probably put significant resources into the drug’s development, although the form of this support is unclear. The actual composition of the serum also remains classified, although Matsumoto may be willing to volunteer that information in the future.